Chelsea Berges
Family Medicine · McAlester, OKNPI 1730562489
Payments from drug & device makers
Across 267 payments — averaging $24.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Novo Nordisk$606
- AbbVie$558
- GSK$387
- Lilly USA, LLC$295
- AstraZeneca$192
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$2,40037%
- Food & beverage$3,96161%
- Education$1272%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 26 | $2,724 |
| Novo Nordisk | 41 | $606 |
| AbbVie(2 entities) | 42 | $558 |
| GSK | 30 | $387 |
| Lilly USA, LLC | 21 | $295 |
| AstraZeneca | 12 | $192 |
| Boehringer Ingelheim | 10 | $191 |
| Amgen | 10 | $177 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $169 |
| Sanofi-aventis U.S. LLC | 8 | $115 |
| Antares Pharma, Inc. | 5 | $110 |
| Johnson & Johnson | 6 | $97 |
| Novartis | 5 | $94 |
| Astellas Pharma US Inc | 1 | $85 |
| Amarin Pharma, Inc. | 3 | $71 |
| Gilead | 3 | $58 |
| Supernus Pharmaceuticals, Inc. | 3 | $57 |
| Mylan Specialty L.p. | 3 | $55 |
| Eisai Inc. | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Bayer | 3 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $21 |
| QOL Medical, LLC | 1 | $17 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Alk-abello, Inc | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COLOGUARD$2,400
How this compares
$6,488 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 31 | $50,222 |
| OzempicSemaglutide | 27 | $49,896 |
| MounjaroTirzepatide | 28 | $45,070 |
| TrulicityDulaglutide | 15 | $37,436 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $36,089 |
| XareltoRivaroxaban | 12 | $13,628 |
| BelsomraSuvorexant | 12 | $12,295 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $9,410 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 187 | $6,726 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 203 | $5,802 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $5,390 |
| DayvigoLemborexant | 12 | $3,843 |
| Duloxetine Hcl | 59 | $3,335 |
| Gabapentin | 84 | $1,902 |
| Pioglitazone Hcl | 38 | $1,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $295 | $82,50543 claims |
| Boehringer IngelheimJardiance | $191 | $50,22231 claims |
| Novo NordiskOzempic | $606 | $49,89627 claims |
| GSKTrelegy Ellipta | $387 | $36,08942 claims |
| Johnson & JohnsonXarelto | $97 | $13,62812 claims |
| MerckBelsomra | $17 | $12,29512 claims |
| Eisai Inc.Dayvigo | $51 | $3,84312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in McAlester
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.